TEVA-ZOLMITRIPTAN 2.5 MG
ZOLMITRIPTAN : 2.5 MG · DIN 02313960 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-ZOLMITRIPTAN?
TEVA-ZOLMITRIPTAN 2.5 MG contains ZOLMITRIPTAN : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02313960, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-ZOLMITRIPTAN used for?
Acute treatment of migraine attacks with or without aura in adults. Not for prophylactic therapy or management of hemiplegic, basilar, or ophthalmoplegic migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02313960 |
|---|---|
| Brand name | TEVA-ZOLMITRIPTAN |
| Generic / active ingredient | ZOLMITRIPTAN : 2.5 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC03 ZOLMITRIPTAN |
| AHFS class | 28:32.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Jun-2011 |
| Original market date | 2011-06-07 00:00:00 |
How is it administered?
Recommended adult starting dose: 2.5 mg. Max single dose: 5 mg. May repeat after 2 hours if headache returns. Max 10 mg in 24 hours. Swallow tablet with water or dissolve OD tablet on tongue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (Section 11 is listed in TOC but content is missing). Typically 15-30°C based on standard Teva monographs.
How is it supplied?
Blister packs of 6 tablets.
Contraindications
Ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; valvular heart disease; arrhythmias; uncontrolled/severe hypertension; within 24h of other 5-HT1 agonists or ergot-type meds.
Warnings and precautions
Risk of myocardial ischemia/infarction, cardiac arrhythmias, and angina pectoris. Cerebrovascular events (stroke, hemorrhage). Risk of medication overuse headache. Potential for sedation.
Is ZOLMITRIPTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02CC03 ZOLMITRIPTAN. 15 of 45 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-ZOLMITRIPTAN | 2.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02481030 |
| BIO-ZOLMITRIPTAN | 2.5 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02512831 |
| JAMP-ZOLMITRIPTAN | 2.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421623 |
| MAR-ZOLMITRIPTAN | 2.5 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02399458 |
| MINT-ZOLMITRIPTAN | 2.5 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02419521 |
| NAT-ZOLMITRIPTAN | 2.5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02421534 |
| NRA-ZOLMITRIPTAN | 2.5 MG | TABLET | NORA PHARMA INC | MARKETED | DIN 02489392 |
| SANDOZ ZOLMITRIPTAN | 2.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02362988 |
| SANDOZ ZOLMITRIPTAN ODT | 2.5 MG | TABLET (ORALLY DISINTEGRATING) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02362996 |
| TEVA-ZOLMITRIPTAN OD | 2.5 MG | TABLET (ORALLY DISINTEGRATING) | TEVA CANADA LIMITED | MARKETED | DIN 02342545 |
Who else supplies ZOLMITRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ZOLMITRIPTAN appears in 99 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.